table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
adjuvant therapies
anticoagulant X-COVID-19
anticoagulant, curative dose COALIZAO ACTION ATTACC, ACTIV-4a, and REMAP-CAP ... COVID-PACT REMAP-CAP, ACTIV-4a, ATTACC ...
anticoagulation, intermediate prophylactic dose INSPIRATION
heparin at therapeutic dose RAPID ... ATTACC ... REMAP-CAP Anticoagulation ACTIV-4a ...

2 studies excluded by filtering options 1

5355 Paranjpe, 2020 1134not a RCThigh risk of bias
6283 Lynn, 2020 0130selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons